OpenAlex
PricingAboutJobs
Log inGet started
Work

Cognition of apalutamide + ADT treatment responders versus non-responders.

HTML

Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2026.44.16_suppl.5085
Authors: Arun Azad, Marco Antonio Badillo, Alicia K. Morgans, Dana Rathkopf, Karie Runcie, Geoffrey Gotto, Axel Stuart Merseburger, Alex Dos Santos, Jingwei Li, Sukie Shopeju, Meenakshi Chatterjee, Rana Zia Ur Rehman, Daniel P. Sanchez, Bhavini Patel, Amitabha Bhaumik, Vasanth Thirugnanam, Yanran Huo, Ashita S. Batavia, Mark A. Wildgust, Neeraj Agarwal
Institutions: Peter MacCallum Cancer Centre, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Columbia University Irving Medical Center, University of Calgary, University Hospital Schleswig-Holstein, Johnson & Johnson (United States), Johnson & Johnson (Germany), Johnson & Johnson (United Kingdom), Johnson & Johnson (Australia), University of Utah, Huntsman Cancer Institute
Language: English

Topic: Cancer-related cognitive impairment studies
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
SDG: Good health and well-being

Open Access status: closed

Funder: Johnson and Johnson
OpenAlex ID: W7162495388
Cites:
Cited by:
Related to:
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms